paracetamol and codeine phosphate

CLINICAL USE


Analgesic

DOSE IN NORMAL RENAL FUNCTION

1–2 tablets up to 4 times a day

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Paracetamol: 151.2; codeine: 317.4 (codeine phosphate 406.4)
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Paracetamol: 20–30; codeine: 7
  • %Excreted unchanged in urine &nbsp &nbsp : Paracetamol: <5; codeine: 0
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :Paracetamol: 1–1.2; codeine: 3–4
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :Paracetamol: 1–4/Unchanged; codeine: 2.5–4/13

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    Available in 2 strengths: (1) 8/500; 8 mg codeine phosphate/500 mg paracetamol, (2) 30/500; 30 mg codeine phosphate/500 mg paracetamol30/500 formulation: may cause drowsiness, due to increased cerebral sensitivity in patients with renal failure

    OTHER INFORMATION

    Effervescent formulations of Solpadol and Tylex (30/500) should be avoided in renal impairment. They contain 16.9 mmol and 13.6 mmol sodium per tablet respectivelyIn renal impairment, opioid analgesics may produce a prolonged effect with increased cerebral sensitivityIncreased risk of constipation in ERF especially with 30/500 preparation